Deutzmann, Anja http://orcid.org/0000-0002-3271-1427
Sullivan, Delaney K. http://orcid.org/0000-0002-8359-6705
Dhanasekaran, Renumathy http://orcid.org/0000-0001-8819-7511
Li, Wei http://orcid.org/0000-0002-2163-7903
Chen, Xinyu
Tong, Ling
Mahauad-Fernandez, Wadie D.
Bell, John
Mosley, Adriane
Koehler, Angela N. http://orcid.org/0000-0001-6980-5534
Li, Yulin http://orcid.org/0000-0003-3479-9909
Felsher, Dean W. http://orcid.org/0000-0003-2496-523X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R35CA253180, R01CA089305, R01CA170378, R01CA184384, P50CA114747, K22CA207598, P30-CA14051)
Lymphoma Research Foundation (Post-doctoral Fellowship Award)
Cancer Prevention and Research Institute of Texas (RP200472)
MIT Center for Precision Cancer Medicine
Article History
Received: 20 August 2019
Accepted: 12 January 2024
First Online: 1 February 2024
Competing interests
: A.N.K. is a founder of Kronos Bio and a member of its scientific advisory board. A.N.K. is a founder of 76Bio, serving on the scientific advisory board and board of directors. A.D., Y.L., and D.W.F. are inventors on a patent related to the method identifying MYC synthetic lethal interactions described in this work (Patent number 11576912). The remaining authors declare no competing interests.